Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$17.79 - $30.86 $1.51 Million - $2.62 Million
84,964 Added 128.33%
151,171 $2.8 Million
Q4 2023

Feb 13, 2024

BUY
$20.78 - $31.77 $185,108 - $283,007
8,908 Added 15.55%
66,207 $2.07 Million
Q3 2023

Nov 14, 2023

BUY
$20.84 - $33.47 $74,503 - $119,655
3,575 Added 6.65%
57,299 $1.19 Million
Q2 2023

Aug 14, 2023

BUY
$17.8 - $25.65 $956,287 - $1.38 Million
53,724 New
53,724 $1.29 Million
Q3 2022

Nov 10, 2022

BUY
$14.11 - $18.27 $380,052 - $492,102
26,935 New
26,935 $441,000
Q2 2022

Aug 04, 2022

SELL
$13.01 - $27.22 $142,108 - $297,324
-10,923 Closed
0 $0
Q1 2022

May 11, 2022

BUY
$20.94 - $27.5 $228,727 - $300,382
10,923 New
10,923 $265,000
Q4 2020

Feb 09, 2021

SELL
$41.04 - $56.79 $215,788 - $298,601
-5,258 Closed
0 $0
Q3 2020

Nov 16, 2020

SELL
$36.42 - $57.0 $171,538 - $268,470
-4,710 Reduced 47.25%
5,258 $217,000
Q2 2020

Aug 06, 2020

BUY
$39.26 - $52.73 $391,343 - $525,612
9,968 New
9,968 $483,000
Q1 2020

May 14, 2020

SELL
$31.65 - $46.87 $2.95 Million - $4.36 Million
-93,099 Closed
0 $0
Q4 2019

Feb 13, 2020

SELL
$36.21 - $51.4 $1.61 Million - $2.28 Million
-44,370 Reduced 32.28%
93,099 $3.98 Million
Q3 2019

Nov 14, 2019

BUY
$22.22 - $44.01 $2.43 Million - $4.81 Million
109,225 Added 386.72%
137,469 $4.95 Million
Q2 2019

Aug 12, 2019

BUY
$23.32 - $28.12 $473,396 - $570,836
20,300 Added 255.54%
28,244 $755,000
Q1 2019

May 15, 2019

BUY
$16.17 - $27.38 $128,454 - $217,506
7,944 New
7,944 $213,000
Q4 2017

Feb 12, 2018

SELL
$26.84 - $39.14 $950,216 - $1.39 Million
-35,403 Closed
0 $0
Q3 2017

Oct 16, 2017

BUY
$29.49 - $38.37 $1.04 Million - $1.36 Million
35,403
35,403 $1.33 Million

Others Institutions Holding ACAD

About ACADIA PHARMACEUTICALS INC


  • Ticker ACAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 161,843,008
  • Market Cap $2.39B
  • Description
  • ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...
More about ACAD
Track This Portfolio

Track Seven Eight Capital, LP Portfolio

Follow Seven Eight Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Seven Eight Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Seven Eight Capital, LP with notifications on news.